Royal Bank Of Canada Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by Royal Bank Of Canada from $112.00 to $116.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock.

Several other analysts have also issued reports on KYMR. Mizuho upped their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Stifel Nicolaus lifted their price target on shares of Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Raymond James Financial restated an “outperform” rating on shares of Kymera Therapeutics in a report on Thursday. Bank of America upped their price objective on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the company a “buy” rating in a research note on Monday, September 14th. Finally, Loop Capital set a $132.00 target price on shares of Kymera Therapeutics in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $137.92.

Kymera Therapeutics Stock Up 3.3%

Shares of KYMR stock opened at $126.63 on Friday. The business has a 50-day moving average price of $114.93 and a two-hundred day moving average price of $96.35. Kymera Therapeutics has a 12-month low of $55.66 and a 12-month high of $130.05. The firm has a market cap of $10.53 billion, a P/E ratio of -34.98 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.65%. Kymera Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.94) earnings per share. As a group, research analysts expect that Kymera Therapeutics will post -3.85 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In related news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 15.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Merck & Co. Inc. bought a new position in shares of Kymera Therapeutics during the second quarter valued at approximately $88,544,161. Legal & General Group Plc purchased a new stake in Kymera Therapeutics in the second quarter worth $4,155,000. Deutsche Bank AG bought a new stake in Kymera Therapeutics in the second quarter valued at $12,161,000. Eagle Health Investments LP bought a new stake in Kymera Therapeutics in the second quarter valued at $19,052,000. Finally, Bank of America Corp DE bought a new stake in Kymera Therapeutics in the second quarter valued at $43,378,000.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.